Forensic Toxicology

, Volume 30, Issue 2, pp 114–125 | Cite as

Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products

  • Nahoko Uchiyama
  • Maiko Kawamura
  • Ruri Kikura-Hanajiri
  • Yukihiro Goda
Original Article

Abstract

Two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA, 1) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, 2), have been identified as designer drugs in illegal products being sold in Japan. The identification was based on liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), high-resolution MS and nuclear magnetic resonance (NMR) analyses. Both mass and NMR spectrometric data revealed that 1 was 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide, and 2 was 1-pentyl-N-tricyclo[3.3.3.1.3,7]dec-1-yl)-1H-indazole-3-carboxamide. Although many of the synthetic cannabinoids detected in illegal products, such as JWH-018, have a 3-carbonyl indole moiety, compounds 1 and 2 are a new type of synthetic cannabinoid having an amide and an adamantyl group, and 2 also has an indazole group in place of an indole group. There has been no synthetic, chemical, or biological information about 1 or 2 until now, making this the first report of these cannabimimetic compounds (1 and 2) as designer drugs. In addition, five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, are also described herein as newly distributed designer drugs in Japan.

Keywords

N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide AM-1220 AM-2233 AM-1241 AM-1248 

References

  1. 1.
    EMCDDA (2009) EMCDDA action on new drugs briefing paper: understanding the ‘Spice’ phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon). http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20—%20final%20version.pdf. Accessed April 2010
  2. 2.
    Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 57:439–441PubMedCrossRefGoogle Scholar
  3. 3.
    Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRefGoogle Scholar
  4. 4.
    Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRefGoogle Scholar
  5. 5.
    Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58–63PubMedCrossRefGoogle Scholar
  6. 6.
    Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31–38PubMedCrossRefGoogle Scholar
  7. 7.
    Dresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R, Auwärter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194PubMedCrossRefGoogle Scholar
  8. 8.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2011) Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol 29:25–37CrossRefGoogle Scholar
  9. 9.
    Kikura-Hanajiri R, Uchiyama N, Goda Y (2011) Survey of current trends in the abuse of psychotropic substances and plants in Japan. Legal Med 13:109–115PubMedCrossRefGoogle Scholar
  10. 10.
    Uchiyama N, Kikura-Hanajiri R, Goda Y (2011) Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB1 and CB2 receptors. Chem Pharm Bull 59:1203–1205PubMedCrossRefGoogle Scholar
  11. 11.
    Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Hamano T (2011) Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29:95–110CrossRefGoogle Scholar
  12. 12.
    Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Hamano T (2011) Identification and quantitation of a benzoylindole(2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 29:132–141CrossRefGoogle Scholar
  13. 13.
    Ernst L, Schiebel HM, Theuring C, Lindigkeit R, Beuerle T (2011) Identification and characterization of JWH-122 used as new ingredient in “Spice-like” herbal incenses. Forensic Sci Int 208:e31–e35PubMedCrossRefGoogle Scholar
  14. 14.
    Bononi M, Belgi P, Tateo F (2011) Analytical data for identification of the cannabimimetic phenylacetylindole JWH-203. J Anal Toxicol 35:360–363PubMedCrossRefGoogle Scholar
  15. 15.
    EMCDDA (2011) EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA EMCDDA-Europol, Lisbon, May 2011. http://www.emcdda.europa.eu/attachements.cfm/att_132857_EN_EMCDDA-Europol%20Annual%20Report%202010A.pdf. Accessed Dec 2011
  16. 16.
    United Nations Office on Drugs and Crime (UNODC) (2011) Synthetic Cannabinoids in Herbal Products. April 2011. http://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf. Accessed May 2011
  17. 17.
    EMCDDA (2011) Online sales of new psychoactive substances/’legal highs’: summary of results from the 2011 multilingual snapshots., Lisbon, November 2011. http://www.emcdda.europa.eu/attachements.cfm/att_143801_EN_SnapshotSummary.pdf. Accessed Nov 2011
  18. 18.
    Nakajima J, Takahashi M, Seto T, Yoshida M, Kanai C, Suzuki J, Hamano T (2012) Identification and quantitation of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone, with other synthetic cannabinoids in unregulated “herbal” products circulated in the Tokyo area. Forensic Toxicol 30:33–44CrossRefGoogle Scholar
  19. 19.
    Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, Balla J (2012) Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary. Forensic Sci Int 214:27–32PubMedCrossRefGoogle Scholar
  20. 20.
    Kneisel S, Westphal F, Moosmann B, Brecht V, Bisel P, Vidal C, Jacobsen-Bauer A, Bork WR, Auwärter V (2011) Cannabimimetics II: mass spectra and ATR-IR spectra of new compounds between the end of 2010 and late 2011. TIAFT Bull 41:29–38Google Scholar
  21. 21.
    Grigoryev A, Kavanagh P, Melnik A (2011) The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal. doi:10.1002/dta.350
  22. 22.
    Huffman JW (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. In: Reggio PH (ed) The cannabinoid receptors. Humana Press, New York, pp 49–94CrossRefGoogle Scholar
  23. 23.
    Makriyannis A, Lui Q (2003) Patent: WO/2003/035005 May, 2003. Heteroindanes: a new class of potent cannabimimetic ligandsGoogle Scholar
  24. 24.
    Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, Strassle BW, Cummons TA, Piesla MJ, Harrison JE, Whiteside GT, Kennedy JD (2007) Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151:1061–1070PubMedCrossRefGoogle Scholar
  25. 25.
    Makriyannis A, Deng H (2002) Patent: WO/2002/060447, August 2002. Receptor selective cannabimimetic aminoalkylindolesGoogle Scholar
  26. 26.
    Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG (2005) Synthesis and structure–activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem 48:5813–5822PubMedCrossRefGoogle Scholar
  27. 27.
    Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, Deschamps JR, Flippen-Anderson JL, Gatley SJ, Makriyannis A (2005) Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 48:6386–6392PubMedCrossRefGoogle Scholar
  28. 28.
    Järbe TU, Deng H, Vadivel SK, Makriyannis A (2011) Cannabinergic aminoalkylindoles, including AM678 = JWH018 found in ‘Spice’, examined using drug (Δ9-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol 22:498–507PubMedCrossRefGoogle Scholar
  29. 29.
    Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O’Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J (2007) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50:3851–3856PubMedCrossRefGoogle Scholar
  30. 30.
    Liu J, Obando D, Liao V, Lifa T, Codd R (2011) The many faces of the adamantyl group in drug design. Eur J Med Chem 46:1949–1963PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer 2012

Authors and Affiliations

  • Nahoko Uchiyama
    • 1
  • Maiko Kawamura
    • 1
  • Ruri Kikura-Hanajiri
    • 1
  • Yukihiro Goda
    • 1
  1. 1.National Institute of Health SciencesTokyoJapan

Personalised recommendations